The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities [0.03%]
癌症中的神经免疫轴：从机制到治疗机遇
Chunyu Zhang,Xiangdong Guo,Peikun Liu et al.
Chunyu Zhang et al.
In recent years, neural mechanisms involved in tumor initiation, progression, and immune regulation have garnered growing attention, fueling the rapid advancement of the burgeoning interdisciplinary domain of neuro-oncology. As a central co...
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? [0.03%]
嵌合抗原受体T细胞疗法在实体瘤中的挑战与局限性：为何仅限于血液系统恶性肿瘤？
Manh-Cuong Vo,Van-Dinh-Huan Tran,Van-Tan Nguyen et al.
Manh-Cuong Vo et al.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering a highly personalized and potent immunotherapeutic approach. To date, the U.S. Food and Drug Administration has approved...
Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution [0.03%]
近期CAR-MSCs的研究进展：细胞免疫治疗的新引擎
Ying Chen,Jing Li,Yingying Ma et al.
Ying Chen et al.
In recent years, the development of chimeric antigen receptor (CAR) technology has greatly promoted the progress of cellular immunotherapy. Among them, CAR-T cell therapy has shown remarkable clinical effects in the treatment of hematologic...
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies [0.03%]
克隆性血细胞增多的种族差异及其对血液系统恶性肿瘤的影响
Zijian Zhang,Chao Cheng
Zijian Zhang
Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for hematologic malignancies (HM), but its distribution and clinical implications across diverse ancestries remain poorly characterized. In this study, we investi...
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia [0.03%]
B细胞成熟抗原是急性髓系白血病免疫治疗的新靶点
Ashley Varkey,Manpreet Bariana,Mark Batistick et al.
Ashley Varkey et al.
B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In t...
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies [0.03%]
基因组编辑的同种异体CAR-T细胞：癌症免疫疗法的下一代疗法
Jingchao Su,Yifei Zeng,Zhuojin Song et al.
Jingchao Su et al.
Chimeric Antigen Receptor T (CAR-T) cell therapy has revolutionized cancer immunotherapy, particularly in hematological malignancies. However, the clinical application of autologous CAR-T cells faces significant high cost and manufacturing ...
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors [0.03%]
HCB101：一种针对CD47-SIRPα通路的新型强效配体陷捕型融合蛋白，具有高度安全性和临床前抗血液系统和实体肿瘤活性
Jiin-Tarng Wang,Chi-Ling Tseng,Han-Fang Teng et al.
Jiin-Tarng Wang et al.
Cluster of differentiation 47 (CD47) delivers an inhibitory signal that suppresses phagocytosis and prevents immune clearance of tumor cells by interacting with signal regulatory protein alpha (SIRPα) on myeloid cells. Although blockade of...
Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity [0.03%]
靶向三阴性乳腺癌的胎盘血CD34⁺多能造血干细胞来源的以mesothelin为靶点、具有强抗肿瘤活性的CAR-NKT细胞疗法
Yan-Ruide Li,Xinyuan Shen,Yichen Zhu et al.
Yan-Ruide Li et al.
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of ER, PR, and HER2 expression. Its aggressive behavior, high degree of tumor heterogeneity, and immunos...
Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy [0.03%]
肝细胞癌的免疫联合疗法：免疫检查点、TKI和化疗之间的协同作用
Suoyi Dai,Yuhang Chen,Wenxun Cai et al.
Suoyi Dai et al.
Combination therapy is rapidly becoming the cornerstone of hepatocellular carcinoma (HCC) treatment. Immune checkpoint inhibitors (ICIs) have emerged as a central strategy in systemic therapy, yet their efficacy as monotherapies remains lim...
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives [0.03%]
肿瘤新抗原和突变负荷在癌症免疫治疗中的作用：进展、机制与展望
Shengbo Sun,Lanchun Liu,Jingkang Zhang et al.
Shengbo Sun et al.
Cancer immunotherapy has revolutionized oncology by leveraging the immune system to combat tumors. Among various biomarkers, neoantigens and tumor mutational burden (TMB) have emerged as critical factors in tailoring personalized treatments...